Pdl Biopharma Inc: (NASD: PDLI)

$8.20

0.09 (1.11%)

Volume 2,068,112

May 14 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		8.09 - 8.21
	
		52wk Low - High
		6.16 - 8.43
	
		Previous Close
		8.11
	
		Avg. Volume
		1,654,454
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.14 B
	
		Div - Yield
		0.60 - 7.40
	
		Beta
		0.44
	
		PE (Forward)
		4.73
	
		Current Year Est.
		1.72
	
		Quarterly Earnings ESP 
		-1.85%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		79 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            4.73
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            1.72
                        
                            Current Quarter Estimate
                            0.54
                        
                            Most Accurate Estimate
                            0.53
                        
                            Earnings ESP 
                            -1.85%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            1.55
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.   
Full PDLI Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
PDLI Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.54	0.40	1.72	1.93
Number of Estimates	2	2	2	2
Low Estimate	0.53	0.39	1.70	1.86
High Estimate	0.55	0.41	1.73	NA
Year Ago EPS	0.53	0.32	1.47	1.72
EPS Growth	1.89%	25.00%	16.67%	12.24%

More PDLI Estimates

Average Earnings Estimates for PDLI

EPS Growth for PDLI

Industry Analysis

Name	Symbol	Previous Close
PDL BIOPHARMA	PDLI	8.11
AETERNA ZENTARS	AEZS	1.87
ANIKA THERAPEUT	ANIK	13.90
GENTIUM SPA-ADR	GENT	8.31
NOVELOS THERAPT	NVLT	0.44
AASTROM BIOSCI	ASTM	0.60
ACHILLION PHARM	ACHN	7.25
AFFYMAX INC	AFFY	1.31
ALEXION PHARMA	ALXN	104.86
ALKERMES INC	ALKS	31.47

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

PDL BioPharma Misses Earnings Ests

May 13, 2013

PDLI Guides Q1 Royalty Revenue

Mar 12, 2013

PDLI Beats on Higher Revenues

Mar 06, 2013

Company News for March 05, 2013

Mar 05, 2013

PDLI Guides Q4 Royalty Rev to $86M

Dec 07, 2012

Bearish MACD for PDL BioPharma Inc.

Dec 06, 2012

PDLI's EPS In Line, Revenue Misses

Nov 07, 2012

PDLI-AxoGen Complete Financing Deal

Oct 10, 2012

More PDLI Zacks Commentary

Financials

EPS TTM	1.55
Sales	375
Net Income	225
Price/Earnings	5.23
Price/Book	NA
Price/Cash Flow	4.95
Price/Sales	2.92

More PDLI Financials

News

PDL BioPharma Makes a Move: Up 1.7% - Financial News Network Online - Market Movers

May 13, 2013

Alkermes has the Lowest PEG Ratio in the Biotechnology Industry (ALKS, PDLI, UTHR) - Financial News Network Online - News Corner

May 10, 2013

PDL BioPharma IncCorporate Event Announcement Notice - Wall Street Horizon

May 10, 2013

PDL BioPharma appoints vice president and CFO - Datamonitor

May 10, 2013

PDL BioPharma Announces First Quarter 2013 Financial Results - Pr Newswire

May 9, 2013

PDL BioPharma Ranks the Highest in Terms of Revenue Per Employee in the Biotechnology Industry (PDLI, GILD, PCYC) - Financial News Network Online - News Corner

May 8, 2013

PDL BioPharma Shares Climbing Higher, Up 1.5% - Financial News Network Online - Market Movers

May 8, 2013

PDLI, AIRM, NKTR, SLXP, CDR, OLP Expected To Be Up After Next Earnings Releases - M2

May 8, 2013

See All News Stories on PDLI

Broker Recommendations

Current ABR	3.00
ABR (Last Week)	3.00
# of recs in ABR	4
Average Target Price	6.67
Industry Rank by ABR	79 out of 265
Rank in Industry	38 out of 155

More PDLI Broker Recommendations

Day Low - High	8.09 - 8.21
52wk Low - High	6.16 - 8.43
Previous Close	8.11
Avg. Volume	1,654,454
Industry	MED-BIOMED/GENE
Market Cap	1.14 B
Div - Yield	0.60 - 7.40
Beta	0.44
PE (Forward)	4.73
Current Year Est.	1.72
Quarterly Earnings ESP	-1.85%

PE (Forward)	4.73
PEG Ratio	NA
Current Year Est.	1.72
Current Quarter Estimate	0.54
Most Accurate Estimate	0.53
Earnings ESP	-1.85%
Next Earnings Report Date	08-08-2013
EPS Last Year	1.55
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Pdl Biopharma Inc: (NASD: PDLI)

$8.20

0.09 (1.11%)

Volume 2,068,112

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations